A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders

Kidney International

Volumn 70, Issue 3, 2006, Pages 423-431

  Besbas, N ^a   Karpman, D ^b   Landau, D ^c   Loirat, C ^d   Proesmans, W ^e   Remuzzi, G ^f   Rizzoni, G ^g   Taylor, C M ^h   Van De Kar, N ⁱ   Zimmerhackl, L B ^j  

^a ANKARA UNIVERSITY   (Turkey)

^b LUND UNIVERSITY   (Sweden)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d HÔPITAL ROBERT DEBRÉ   (France)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^g BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^h BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF INNSBRUCK   (Austria)

more..

Author keywords

Etiology; Hemolytic uremic syndrome; Thrombotic thrombocytopenic purpura

Indexed keywords

ANTITHROMBOCYTIC AGENT; CALCINEURIN INHIBITOR; CLOPIDOGREL; COBALAMIN; COMPLEMENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GEMCITABINE; MITOMYCIN; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; QUININE; RAPAMYCIN; SHIGA TOXIN; SIALIDASE; TACROLIMUS; TICLOPIDINE; VEROTOXIN; VIRUS T ANTIGEN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANAMNESIS; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CITROBACTER FREUNDII; CLINICAL FEATURE; COMPLEMENT DISORDER; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; ENZYME DEFICIENCY; ESCHERICHIA COLI; GENE MUTATION; GENETIC DISORDER; GLOMERULOPATHY; GRAFT VERSUS HOST REACTION; HELLP SYNDROME; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOSUPPRESSIVE TREATMENT; INBORN ERROR OF METABOLISM; IONIZING RADIATION; MALIGNANT NEOPLASTIC DISEASE; NOMENCLATURE; NONHUMAN; PATHOGENESIS; PEDIATRICS; PLASMAPHERESIS; PREGNANCY; PRIORITY JOURNAL; REGISTER; REVIEW; SHIGELLA DYSENTERIAE; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSPLANTATION; VITAMIN METABOLISM;

ANIMALS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 33746508999     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001581     Document Type: Review

References (142)

1. Gasser C, Gautier E, Steck A et al. Hämolytisch-urämische syndrome: bilaterale nierenrinden nekrosen bei akuten erworbenen hämolytischen anämien. Schweitz Med Wochenschr 1955; 85: 905-909.
2. Moschcowitz E. An acute febrile pleiochromic anemia with hyalin thrombosis of the terminal arterioles and capillaries. An undescribed disease. Arch Intern Med 1925; 36: 89-93.
3. Symmers WStC. Thrombotic microangiopathic haemolytic anaemia (thrombotic microangiopathy). Br Med J 1952; 2: 897-903.
4. Habib R. Pathology of the hemolytic uremic syndrome. In: Kaplan B, Trompeter R, Moake J (eds). Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. Marcel Dekker: New York, 1992, pp 315-353.
5. Karmali MA, Petric M, Lim C et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985; 151: 775-782.
6. Butler T, Islam MR, Azad MA et al. Risk factors for development of hemolytic uremic syndrome during shigellosis. J Pediatr 1987; 110: 894-897.
7. Bhimma R, Rollins NC, Coovadia HM, Adhikari M. Post-dysenteric hemolytic uremic syndrome in children during an epidemic of Shigella dysentery in Kwazulu/Natal. Pediatr Nephrol 1997; 11: 560-564.
8. Tschape H, Prager R, Strekel W et al. Verotoxigenic Citrobacter freundii associated with severe gastroenteritis and cases of haemolytic uraemic syndrome in a nursery school: green butter as the infection source. Epidemiol Infect 1995; 114: 441-450.
9. Griffin P, Tauxe R. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol Rev 1991; 13: 60-98.
10. Rowe PC, Orrbine E, Wells GA et al. Epidemiology of hemolytic-uremic syndrome in Canadian children from 1986 to 1988. The Canadian Pediatric Kidney Disease Reference Centre. J Pediatr 1991; 119: 218-224.
11. Milford D, Taylor CM, Guttridge B et al. Haemolytic uraemic syndromes in the British Isles 1985-8: association with verocytotoxin producing Escherichia coli. Part 1: clinical and epidemiological aspects. Arch Dis Child 1990; 65: 716-721.
12. Decludt B, Bouvet P, Mariani-Kurkdjian P et al. Haemolytic uraemic syndrome and Shiga toxin-producing Escherichia coli infection in children in France. The Societe de Nephrologie Pediatrique. Epidemiol Infect 2000; 124: 215-220.
13. Elliot EJ, Robins-Browne RM, O'Loughlin EV et al. Nationwide study of haemolytic uraemic syndrome: clinical, microbiological and epidemiological features. Arch Dis Childh 2001; 85: 125-131.
14. Friedrich AW, Bielaszewska M, Zhang WL et al. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis 2002; 185: 74-84.
15. Beutin L, Krause G, Zimmerman S et al. Characterization of shiga toxin-producing Escherichia coli strains isolated from human patients in Germany over a 3-year period. J Clin Microbiol 2004; 42: 1099-1108.
16. Lynn R, O'Brien SJ, Taylor CM et al. Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerg Infect Dis 2005; 11: 590-596.
17. Proulx F, Sockett P. Prospective surveillance of Canadian children with the haemolytic uraemic syndrome. Pediatr Nephrol 2005; 20: 786-790.
18. Lopez EL, Diaz M, Grinstein S et al. Hemolytic uremic syndrome and diarrhea in Argentine children: role of shiga-like toxins. J Infect Dis 1989; 160: 469-475.
19. Chandler W, Jelacic S, Boster D et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002; 346: 23-32.
20. Richardson S, Karmali M, Becker L et al. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol 1988; 19: 1102-1108.
21. Inward CD, Howie AJ, Fitzpatrick MM et al. Renal histopathology in fatal cases of diarrhoea-associated haemolytic uraemic syndrome. Pediatr Nephrol 1997; 11: 556-559.
22. Garg AX, Suri RS, Barrowman N et al. Long-term renal prognosis of diarrhea-associate haemolytic uremic syndrome. A systemic review, meta-analysis and meta- regression. JAMA 2003; 290: 1360-1370.
23. Brandt J, Wong C, Mihm S et al. Invasive pneumococcal disease and hemolytic uremic syndrome. Pediatrics 2002; 110: 371-376.
24. de Loos F, Huijben KMLC, Van der Kar NCAJ et al. Hemolytic uremic syndrome attributable to Streptococcus pneumonia infection: a novel cause of secondary protein N-glycan abnormalities. Clin Chem 2002; 48: 781-785.
25. Klein PJ, Bulla M, Newman RA et al. Thomsen-Friedenreich antigen in haemolytic uraemic syndrome. Lancet 1977; 2: 1024-1025.
26. Eder A, Manno C. Does red-cell T activation matter? Br J Haematol 2001; 114: 25-30.
27. Pangburn MK. Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement. Immunopharmacology 2000; 49: 149-151.
28. Hellwage J, Jokiranta TS, Friese MA et al. Complement C3b/C3d and cell surface polyanions are recognised by overlapping binding sites on the most carboxyl-terminal domain of complement factor H. J Immunol 2002; 169: 6935-6944.
29. Manuelian T, Hellwage J, Meri S et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in haemolytic uremic syndrome. J Immunol 2002; 169: 6935-6944.
30. Vaziri-Sani F, Hellwage J, Zipfel PF et al. Factor H binds to washed human platelets. J Thromb Haemost 2005; 3: 154-162.
31. Warwicker P, Goodship THJ, Donne RL et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998; 53: 836-844.
32. Rougier N, Kazatchkine MD, Rougier J-P et al. Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol 1998; 9: 2318-2326.
33. Pangburn MK. Localisation of the host recognition functions of complement factor H at the carboxyl terminal: implications for hemolytic uremic syndrome. J Immunol 2002; 169: 4702-4706.
34. Sanchez-Corral P, Gonzales-Rubio C, Rodrigues de Cordoba S, Lopez-Trascasa M. Functional analysis in serum from atypical hemolytic uremic syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol 2004; 41: 81-84.
35. Sanchez-Corral P, Perez-Caballero D, Huarte O et al. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet 2002; 71: 1285-1295.
36. Ault BH, Schmidt BZ, Fowler NL et al. Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J Biol Chem 1997; 272: 25168-25175.
37. Caprioli J, Castelletti F, Bucchioni S et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003; 15: 3385-3395.
38. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A et al. Predisposition to atypical haemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005; 14: 703-712.
39. Landau D, Shalev H, Levy-Finer G et al. Familial haemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr 2001; 138: 12-17.
40. Loirat C, Niaudet P. The risk of recurrent haemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol 2003; 18: 1095-1101.
41. Bresin W, Daina E, Noris M et al. for the International Registry of Recurrent and Familial HUS/TTP. Outcome or renal transplantation in patients with non-Shiga toxin-asociated haemolytic uremic sundrome Prognostic significance of genetic background. Clin J Am Soc Nephrol 2006; 1: 88-99.
42. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J et al. Complement factor I: the susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004; 41: e84.
43. Kavanagh DM, Kemp EJ, Mayland E et al. Mutations in complement factor I predispose to development of atypical haemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 2150-2155.
44. Richards A, Kemp EJ, Liszewski MK et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predisposes to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci USA 2003; 100: 12966-12971.
45. Noris M, Brioschi S, Caprioli J et al. International registry of recurrence and familial HUS/TTP. Familial hemolytic uremic syndrome and an MCP mutation. Lancet 2003; 362: 1542-1547.
46. Zipfel PF, Jokiranta TS, Hellwage J et al. The factor H protein family. Immunopharmacology 1999; 42: 53-60.
47. Kondo C, Mizuno M, Nishikawa K et al. The role of C5a in the development of thrombotic glomerulonephritis in rats. Clin Exp Immunol 2001; 124: 323-329.
48. Nangaku M, Alpers CE, Pippin J et al. CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats. J Am Soc Nephrol 1998; 9: 590-597.
49. Noris M, Ruggenenti P, Perna A et al. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. J Am Soc Nephrol 1999; 10: 281-293.
50. Fremeaux-Bacchi V, Kemp EJ, Goodship JA et al. The development of atypical HUS is influenced by susceptibility factors in factor H and membrane cofactor protein- evidence from two independent cohorts. J Med Genet 2005; 42: 852-856.
51. Dragon-Durey M-A, Loirat C, Cloarec S et al. Anti-factor H autoantibodies associated with atypical haemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 555-563.
52. Moake JL, Byrnes CK, Troll JH et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1435.
53. Moake JL, Byrnes JJ, Troll JH et al. Abnormal VIII:von Willebrand factor pattern in the plasma of patients with the haemolytic uremic syndrome. Blood 1984; 64: 592-598.
54. Furlan M, Robles R, Solenthaler M et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-3103.
55. Furlan MF, Robles R, Galbusera M et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med 1998; 339: 1578-1584.
56. Tsai HM, Chun-Yet Lain E. Antibodies to von Willebrand factor-cleaving protease in actue thrombotic thrombocytopenic purpura. N Engl J Med 1998; 338: 1585-1594.
57. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
58. Mannucci PM, Canciani MT, Forza I et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98: 2730-2735.
59. Fujikawa K, Suzuki H, McMullen B, Chung D. Pufication of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98: 1662-1666.
60. Gerritsen HE, Robles R, Lämmle B, Furlan MF. Partial amino acid sequence of [purified von Willebrand factor-cleaving protease]. Blood 2001; 98: 1654-1661.
61. Levy GC, Nicols WC, Lian EC et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
62. Kokame K, Matsumoto M, Soejima K et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Assoc Soc 2002; 99: 11902-11907.
63. Assink K, Schiphorst R, Allford S et al. Mutationanalysis and clinical implications of von Willebrand factor protease deficiency. Kidney Int 2003; 63: 1995-1999.
64. Schneppenheim R, Budde U, Oyen F et al. Von Willebrand factor cleaving protease and ADAMTS13 mutaions in childhood TTP. Blood 2003; 101: 1845-1850.
65. Zheng X, Chung D, Takayama TK et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-41063.
66. Soejima K, Mimura N, Hirashima M. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem 2001; 130: 475-480.
67. Uemara M, Tatsumi K, Matsumoto M et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005; 106: 922-924.
68. Furlan M, Robles R, Morselli B et al. Recovery and half life of von Willebrand factor-cleaving-protease after plasmatherapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999; 81: 8-13.
69. Tripodi A, Chantarangkul V, Bohm M et al. Measurements of von Willebrand factor cleaving protease (ADAMTS13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004; 2: 1601-1609.
70. Jubinsly PT, Moraille R, Tsai HM. Thrombotic thrombocytopenic purpura in a newborn. J Perinatol 2003; 23: 85-87.
71. George JN, Sadler JE, Lämmle B. Platelets: thrombotic thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program) 2002: 315-342.
72. Rock GA, Shumak KH, Buskard NA et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. A Candadian apheresis study group. N Engl J Med 1991; 325: 393-397.
73. Zheng X, Pallera AM, Goodnough LT et al. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003; 138: 105-108.
74. Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003; 14: 1072-1081.
75. Fakhouri F, Vernant JP, Veyradier A et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005; 106: 1932-1937.
76. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998; 128: 541-544.
77. Bennett CL, Davidson CJ, Raisch DW et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Ann Intern Med 1999; 159: 2524-2528.
78. Tsai HM, Rice L, Sarode R et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000; 132: 7984-7989.
79. Bennet CL, Connors JM, Carwile JM et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Eng J Med 2000; 342: 1773-1777.
80. Baumgartner ER, Wick H, Maurer R et al. Congenital defect in intracellular cobalamin metabolism resulting in homocystinuria and methylmalonic aciduria. A case report and histopathology. Helv Paediatr Acta 1979; 34: 465-482.
81. Russo PA, Doyon J, Sonsino E et al. Inborn errors of cobalamin metabolism and the hemolytic uremic syndrome. In: Kaplan BS, Trompeter RS, Moake JL (eds). Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. Dekker: New York, 1992, pp 255-270.
82. Geraghty MT, Perlman EJ, Martin LS et al. Cobalamin C defect associated with hemolytic-uremic syndrome. J Pediatr 1992; 120: 934-937.
83. Labrune P, Zittoun J, Duvaltier I et al. Haemolytic uraemic syndrome and pulmonary hypertension in a patient with methionine synthase deficiency. Eur J Pediatr 1999; 158: 734-739.
84. Brunelli SM, Meyers KEC, Guttenberg M et al. Cobalamin C deficiency complicated by an atypical glomerulopathy. Pediatr Nephrol 2002; 17: 800-803.
85. Van Hove JL, Van Damme-Lombaerts R, Grunewald S et al. Cobalamin disorder Cbl-C presenting with late-onset thrombotic microangiopathy. Am J Med Genet 2002; 111: 195-201.
86. Gottscall JL, Neahring B, MacFarland JG et al. Quinine-innduced immune thrombocytopenia with haemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature. Am J Hematol 1994; 47: 283-289.
87. Aster RH. Quinine sensitivity. A new cause of the haemolytic uremic syndrome. Ann Int Med 1993; 119: 243-244.
88. Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features and long-term outcomes. Ann Intern Med 2001; 135: 1047-1051.
89. Stroncek DF, Vercellotti GM, Hammerschmidt DE et al. Characterization of multiple quinine-dependent antibodies in a patient with episodic haemolytic uremic syndrome and immune agranuocytosis. Blood 1992; 80: 241-248.
90. Glynne P, Salama A, Chaudhry A et al. Quinine-induced immune thrombocytopenic purpura followed by hemolytic uremic syndrome. Am J Kidney Dis 1999; 33: 133-137.
91. Strauss J, Abitbol C, Zilleruelo G, Montane B. HIV nephropathy. In: Barratt TM, Avner ED, Harmon WE (eds). Pediatric Nephrology. 4th edn, Lippincott, Williams and Wilkinson: Baltimore, 1999, pp 1103-1107.
92. Badesha PS, Saklayen MG. Hemolytic uremic syndrome as a presenting form of HIV infection. Nephron 1996; 72: 472-475.
93. Peraldi MN, Maslo C, Akposso K et al. Acute renal failure in the course of HIV infection: a single institution retrospective study of ninety-two patients and sixty renal biopsie. Nephrol Dial Transplant 1999; 14: 1578-1585.
94. Ray PE, Rakusan T, Loechelt BJ et al. Human immunodeficiency virus (HIV) associated nephropathy in children from the Washington DC. Area: 12 years' experience. Semin Nephrol 1998; 18: 396-405.
95. Sahud MA, Claster S, Liu L et al. Von Willebrand factor cleaving protease inhibitor in a patients with human immunodeficiency syndrome associated thrombotic thrombocytopenic purpura. Br J Haematol 2002; 116: 909-911.
96. Segerer S, Eitner F, Cui Y et al. Cellular injury associated with renal thrombotic microangiopathy in human immunodeficiency virus-infected macaques. J Am Soc Nephrol 2002; 13: 370-378.
97. Carr DJ, Kramer BS, Dragonetti DE. Thrombotic thrombocytopenic purpura associated with metastatic gastric adenocarcinoma: successful management with plasmapheresis. South Med J 1986; 79: 476-479.
98. Mungall S, Mathieson P. Hemolytic uremic syndrome in metastatic adenocarcinoma of the prostate. Am J Kidney Dis 2002; 40: 1334-1336.
99. Majhail NS, Hix JK, Almahameed A. Carcinoma of the colon in a patient presenting with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Mayo Clinc Proc 2002; 77: 873.
100. Lesesne JB, Rothschild N, Erickson B et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989; 7: 781-789.
101. Cavagnaro F, Barriga F. Hemolytic uremic syndrome in a child with leukemia and cytomegalovirus infection. Pediatr Nephrol 2000; 14: 1118-1120.
102. Matsuda Y, Hara J, Miyoshi H et al. Thrombotic microangiopathy associated with reactivation of human herpesvirus-6 following high-dose chemotherapy with autologous bone marrow transplantation in young children. Bone Marrow Transplant 1999; 254: 919-923.
103. Crocker J, Jones EL. Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma. J Clin Pathol 1983; 36: 24-29.
104. Lyman NW, Michaelson R, Viscuso RL et al. Succesful treatment with corticosteroids and intense plasma exchange. Arch Intern Med 1983; 143: 1617-1618.
105. Cattell V. Mitomycin-induced hemolytic uremic kidney. An experimental model in the rat. Am J Pathol 1985; 121: 88-95.
106. Teixeira L, Debourdeau P, Zammit C et al. Gemcitabine-induced thrombotic microangiopathy. Presse Méd 2002; 31: 740-742.
107. Humphreys BD, Sharman JP, Henderson JM et al. Gemctabine-associated thrombotic microangiopathy. Cancer 2004; 100: 2664-2670.
108. Bonser RS, Adu D, Franklin I, McMaster P. Cyclosporin-induced haemolytic uraemic syndrome in liver allograft recipient. Lancet 1984; 2: 1337.
109. Van Buren D, Van Buren CT, Flechner SM et al. De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery 1985; 98: 54-62.
110. Young BA, Marsh CL, Alpers CE, Davis CL. Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation. Am J Kidney Dis 1996; 28: 561-571.
111. Zarifian A, Meleg-Smith S, O'donovan R et al. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 1999; 55: 2457-2466.
112. Trimarchi HN, Truong LD, Brennan S et al. FK506-associated thrombotic microangiopathy. Report of two cases and review of the literature. Transplantation 1999; 67: 539-544.
113. Burke GAA, McGraw ME, MacIver AG. The role of early renal biopsy in cyclosporin induced thrombotic microangiopathy. Pediatr Nephrol 1999; 13: 564-566.
114. Moake JL, Byrnes JJ. Thrombotic microangiopathies associated with drugs and bone marrow transplantation. Hematol Oncol Clin North Am 1996; 10: 485-497.
115. George JN, Li X, McMinn JR et al. Thrombotic thrombocytopenic purpura - haemolytic uremic syndrome following allogenic hematopoetic stem cell transplantation: a diagnostic dilemma. Transfusion 2004; 44: 294-304.
116. Reynolds JC, Agodoa LY, Yuam CM, Abbott KC. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003; 42: 1058-1068.
117. Florman S, Benchimol C, Lieberman K et al. Fulminant recurrence of atypical haemolytic uremic syndrome during a calcineurin inhibito-free immunosuppression regimen. Pediatr Transpl 2002; 6: 352-355.
118. George JN, Vesely SK, Terrell DR. The Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 2004; 41: 60-67.
119. Lattuada A, Rossi E, Calzarossa R, Mannucci PM. Mild to moderate reduction of a von Wllebrab factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003; 88: 1029-1034.
120. Cosmai EM, Puzis L, Tsai H-M, Lian EC-Y. Thrombocytopenic purpura and cardiomyopathy in pregnanacy reversed by combined plasma exchange and infusion. Eur J Haematol 2002; 68: 239-242.
121. Ducloy-Bouthors A-S, Caron C, Subtil D et al. Thrombotic thrombocytopenic purpura: medical and biological monitoring of six pregnancies. Eur J Obstet Gynecol Reprod Biol 2003; 111: 146-152.
122. Veyradier A, Obert B, Houlier A et al. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 1765-1771.
123. Vesely SK, George JN, Lammle B et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-68.
124. Vasoo S, Thumboo J, Fong KY. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: disease activity and the use of cytotoxic drugs. Lupus 2002; 11: 443-450.
125. Banfi G, Bertani T, Boeri V et al. Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Am J Kidney Dis 1991; 18: 240-248.
126. Kawasaki Y, Suzuki J, Nozawa R et al. A 12 year-old girl with hemolytic uremic syndrome as initial symptom of systemic lupus erythematosus and a literature review. Am J Nephrol 2002; 22: 576-580.
127. Espinosa G, Bucciarelli S, Cervera R et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis 2004; 63: 730-736.
128. Amoura Z, Costedoat-Chalumeau N, Veyradier A et al. Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome. Arthritis Rheum 2004; 50: 3260-3264.
129. Ruggenenti P, Galli M, Remuzzi G. Hemolytic uremic syndrome, thrombotic thrombocytopenic purpura and antiphospholipid antibody syndromes. In: Neilson EG and Couser WG (eds). Immunologic Renal Diseases. Lippincot Williams and Wilkins: Philadelphia, 2001, Chapter 49, pp 1173-1201.
130. De Chadarevian JP, Goodyer PR, Kaplan BS. Acute glomerulonephritis and hemolytic uremic syndrome. Can Med Assoc J 1980; 123: 391-394.
131. Proesmans W, Baten E, Van Damme B. A boy with acute renal failure. A case for diagnosis. Pediatr Nephrol 1995; 9: 389-391.
132. Habib R. Pathology of the hemolytic uremic syndrome. In: Kaplan BS, Trompeter RS and Moake JL (eds). Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. Dekker: New York, 1992, pp 341-342.
133. Siegler RL, Brewer ED, Pysher J. Hemolytic uremic syndrome associated with glomerular disease. Am J Kidney Dis 1989; 13: 144-147.
134. Dische FE, Culliford EJ, Parsons V. Haemolytic urmic syndrome and idiopathic membranous glomerulonephritis. Br Med J 1978; 1: 1112-1113.
135. Morita S, Sakai T, Okamoto N et al. Hemolytic uremic syndrome associated with immunoglobulin A nephropathy: a case report and review of cases of haemolytic uremic syndrome with glomerular disease. Intern Med 1999; 38: 495-499.
136. Melnyk AM, Solez K, Kjellstrand CM. Adult hemolytic-uremic syndrome. A review of 37 cases. Arch Intern Med 1995; 155: 2077-2084.
137. Remuzzi G, Galbusera M, Mannucci PM. ADAMTS13 in microangiopathies. Blood 2002; 100: 3842.
138. Ono T, Mimuro J, Madoiwa S et al. Severe deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107: 528-534.
139. Hunt BJ, Lammle B, Nevard CHF, Haycock GB. Von Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost 2001; 85: 975-978.
140. Noris M, Bucchioni S, Galbusera M et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol 2005; 16: 1177-1183.
141. Guigonis V, Fremeaux-Bacchi V, Giraudier S et al. Late-onset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation. Am J Kidney Dis 2005; 45: 588-595.
142. Allford SL, Hunt BJ, Rose P, Machin SJ. (on behalf of the haemostasis and thrombosis task force of the British Committee for Standards in Haematology) Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003; 120: 556-573.